Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized 129Xe MRI in COVID-19 Survivors
NCT04659707Phase 1Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Feb 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hyperpolarized xenon gas in coronavirus disease 2019 (COVID-19), sponsored by University of Kansas Medical Center. Primary endpoint: Ventilation Defect Percentage at 6 months. Started Feb 2021; status: completed.
02
Drugs
hyperpolarized xenon gas
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04659707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659707.